Suvretta Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

Suvretta Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-133,600	Closed	-$3.96M	–	91
2022 Q3	$3.96M	Buy	133,600 +22,087	+20%	+$914K	0.17%	59
2022 Q2	$4.55M	Hold	111,513	–	–	0.17%	66
2022 Q1	$6.11M	Hold	111,513	–	–	0.19%	61
2021 Q4	$10.9M	Buy	111,513 +45,238	+68%	+$8.59M	0.21%	61
2021 Q3	$16.8M	Buy	66,275 +18,571	+39%	+$5.25M	0.29%	53
2021 Q2	$14.8M	Buy	47,704 +26,686	+127%	+$10.8M	0.22%	68
2021 Q1	$13.8M	Buy	+21,018	New	+$13.7M	0.21%	67

Other funds holding BOLT

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2B AUM 117.41% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return